491 related articles for article (PubMed ID: 21779567)
1. Naturally occurring inhibitors against the formation of advanced glycation end-products.
Peng X; Ma J; Chen F; Wang M
Food Funct; 2011 Jun; 2(6):289-301. PubMed ID: 21779567
[TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end product (age) inhibitors and their therapeutic implications in diseases.
Takeuchi M; Yamagishi S; Iwaki M; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2004; 24(2-3):95-101. PubMed ID: 15689055
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases.
Reddy VP; Beyaz A
Drug Discov Today; 2006 Jul; 11(13-14):646-54. PubMed ID: 16793534
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
5. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
7. Substituted benzenediol Schiff bases as promising new anti-glycation agents.
Choudhary MI; Abbas G; Ali S; Shuja S; Khalid N; Khan KM; Atta-ur-Rahman ; Basha FZ
J Enzyme Inhib Med Chem; 2011 Feb; 26(1):98-103. PubMed ID: 20583858
[TBL] [Abstract][Full Text] [Related]
8. The Maillard reaction and its consequences for a living body.
Sztanke K; Pasternak K
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(2):159-62. PubMed ID: 15323185
[TBL] [Abstract][Full Text] [Related]
9. Novel inhibitors of advanced glycation endproducts (part II).
Rahbar S; Yerneni KK; Scott S; Gonzales N; Lalezari I
Mol Cell Biol Res Commun; 2000 Jun; 3(6):360-6. PubMed ID: 11032758
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic intervention in diseases with advanced glycation end products in their pathogenesis].
Zuwała-Jagiełło J
Pol Merkur Lekarski; 2009 Aug; 27(158):152-6. PubMed ID: 19856885
[TBL] [Abstract][Full Text] [Related]
11. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation endproducts (AGEs): Pharmacological inhibition in diabetes.
Peyroux J; Sternberg M
Pathol Biol (Paris); 2006 Sep; 54(7):405-19. PubMed ID: 16978799
[TBL] [Abstract][Full Text] [Related]
13. Skin beautification with oral non-hydrolized versions of carnosine and carcinine: Effective therapeutic management and cosmetic skincare solutions against oxidative glycation and free-radical production as a causal mechanism of diabetic complications and skin aging.
Babizhayev MA; Deyev AI; Savel'yeva EL; Lankin VZ; Yegorov YE
J Dermatolog Treat; 2012 Oct; 23(5):345-84. PubMed ID: 21756141
[TBL] [Abstract][Full Text] [Related]
14. Glycation, carbonyl stress and AGEs inhibitors: a patent review.
Jahan H; Choudhary MI
Expert Opin Ther Pat; 2015; 25(11):1267-84. PubMed ID: 26293545
[TBL] [Abstract][Full Text] [Related]
15. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
16. Toxicity of the AGEs generated from the Maillard reaction: on the relationship of food-AGEs and biological-AGEs.
Chuyen NV
Mol Nutr Food Res; 2006 Dec; 50(12):1140-9. PubMed ID: 17131455
[TBL] [Abstract][Full Text] [Related]
17. The maillard reaction in eye diseases.
Stitt AW
Ann N Y Acad Sci; 2005 Jun; 1043():582-97. PubMed ID: 16037281
[TBL] [Abstract][Full Text] [Related]
18. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of advanced glycation end products (AGEs): potential utility for the treatment of cardiovascular disease.
Yamagishi S; Nakamura K; Matsui T; Ueda S; Noda Y; Imaizumi T
Cardiovasc Ther; 2008; 26(1):50-8. PubMed ID: 18466420
[TBL] [Abstract][Full Text] [Related]
20. The AGE of the matrix: chemistry, consequence and cure.
DeGroot J
Curr Opin Pharmacol; 2004 Jun; 4(3):301-5. PubMed ID: 15140424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
